Marius Pharmaceuticals Receives PDUFA Date for KYZATREX® NDA for Treatment of Hypogonadism
RALEIGH, N.C., March 11, 2021 – Marius Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) goal date of Read More >>
Marius Seeks FDA Approval of Testosterone Therapy
Raleigh-based Marius Pharmaceuticals, led by several former GlaxoSmithKline scientists and executives, is making progress on its first potential drug.Marius has submitted a New Drug Application (NDA) to the U.S. Food and Read More >>
Shah Capital Invests US$11 Million in ReneSola
SHANGHAI, Oct. 2, 2019 /PRNewswire/ — ReneSola Ltd (“ReneSola” or the “Company”) (www.renesolapower.com) (NYSE: SOL), a leading fully integrated solar project developer, today announced that the Company entered into a definitive share purchase Read More >>
Marius Pharmaceuticals Completes Efficacy Portion of its Re-Tune Phase 3 Study Evaluating Their Innovative Oral Testosterone Undecenoate Formulation in Hypogonadal Men
September 26 2018, Raleigh, NC – Marius Pharmaceuticals, a specialty pharmaceutical company, today announced positive preliminary data for their Phase 3 clinical trial evaluating SOV-2012-F1 in men suffering from hypogonadism. Read More >>
Vitamin Shoppe to Appoint New Independent Directors to Board
SECAUCUS, N.J., April 23, 2018 SECAUCUS, N.J., April 23, 2018 /PRNewswire/ — Vitamin Shoppe, Inc. (NYSE: VSI), an omni-channel, specialty retailer and contract manufacturer of nutritional products, today announced that Read More >>